Figure 6
From: Characterization of Brucella abortus mutant strain Δ22915, a potential vaccine candidate
Determination of Brucella antibody and protection by vaccination with mutant strain ∆22915. A Strain ∆22915 induced significantly higher titers of Brucella-specific antibodies than RB51 at all investigated time points. Data were expressed as mean ± SD (n = 5) and analyzed with two-way ANOVA. ***P < 0.001. B Protection efficacy at 12 weeks post vaccination. C Protection efficacy at 16 weeks post vaccination. For protection evaluation, vaccinated mice were challenged with 1 × 104 CFU nalidixic-acid resistant S2308/mouse. One week post challenge, spleens were collected to determine bacterial loads to assess protection efficacy. No bacteria were recovered from the mice of ∆22915-vaccinated group, indicating better protection efficacy than RB51. Data points were individual values of CFU determinations (n = 5) and analyzed using a Student’s t test. **P < 0.01; ***P < 0.001.